To determine the 5-year outcome of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (CNV).
We retrospectively analyzed the medical records of 51 eyes of 51 consecutive patients with myopic CNV who had been treated with IVR with a minimum follow-up period of 5 years after the initial IVR injection. The factors that predicted the best-corrected visual acuity (BCVA) at 5 years after IVR were determined by multiple regression analysis.
The mean age of the subjects was 63.6 years, and the mean axial length was 29.4 mm. The mean number of IVR was 1.6, and 34 eyes (66.7%) had only a single IVR. At the baseline and at the 1-year, 2-year, 4-year, and 5-year period, the mean BCVAs were 20/49, 20/37, 20/41, 20/45, and 20/42, respectively. Stepwise multiple regression analysis showed that the BCVA at 5-year period was significantly correlated with the baseline BCVA, the number of IVR injections, and the size of the CNV-related macular atrophy.
Intravitreal ranibizumab provide a 5-year visual benefit in eyes with myopic CNV compared with the natural course. A lack of enlargement of the CNV-related macular atrophy, a better baseline BCVA, and a minimum number of IVR injections were associated with better visual outcomes.
The vision of 51 eyes with an active choroidal neovascularization was significantly improved over the baseline vision at 1 year after intravitreal injections of ranibiizumab but not at 2, 4, and 5 years. At 5 years, the visual acuity was significantly correlated with the size of the macular atrophy.
*Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan; and
†Department of Ophthalmology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Reprint requests: Tae Yokoi, MD, Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan; e-mail: email@example.com
Supported in part by research grant 15H04993 and 15K15629 from the Japan Society for the Promotion of Science, Tokyo, Japan, and Novartis Phama K.K.
None of the authors has any financial/conflicting interests to disclose.